Kenvue’s (KVUE) “Sector Perform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada restated their sector perform rating on shares of Kenvue (NYSE:KVUE) in a report published on Monday,Benzinga reports. The firm currently has a $24.00 price target on the stock.

Other research analysts have also issued research reports about the stock. Citigroup cut their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. UBS Group decreased their target price on Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research note on Thursday, January 16th. JPMorgan Chase & Co. lifted their price target on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $21.00 to $26.00 in a research report on Monday, January 6th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Stock Down 0.4 %

KVUE opened at $20.74 on Monday. The firm has a market cap of $39.76 billion, a P/E ratio of 37.70, a price-to-earnings-growth ratio of 2.05 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The business has a 50 day moving average price of $21.77 and a 200 day moving average price of $21.96. Kenvue has a twelve month low of $17.67 and a twelve month high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same period in the previous year, the company earned $0.31 earnings per share. Kenvue’s revenue for the quarter was down .4% on a year-over-year basis. Research analysts forecast that Kenvue will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.95%. The ex-dividend date is Wednesday, February 12th. Kenvue’s payout ratio is 149.09%.

Institutional Trading of Kenvue

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Grove Bank & Trust boosted its holdings in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in Kenvue in the 4th quarter valued at $29,000. Riverview Trust Co bought a new stake in Kenvue in the third quarter valued at $30,000. SRS Capital Advisors Inc. raised its stake in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after acquiring an additional 571 shares in the last quarter. Finally, Fortitude Family Office LLC lifted its holdings in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.